Abstract
Topical 0.03% tacrolimus was used for treatment of a Korea Jindo dog diagnosed with pemphigus erythematosus. The dog was slowly improved following application of tacrolimus but did not achieve complete remission until end of this study. No adverse effects on clinical or laboratory parameters were noted during the topical tacrolimus therapy period.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 415-417 |
| Number of pages | 3 |
| Journal | Journal of Veterinary Medical Science |
| Volume | 70 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Canine
- Pemphigus erythematosus
- Topical 0.03% tacrolimus
ASJC Scopus subject areas
- veterinary(all)
Cite this
Topical 0.03% tacrolimus for treatment of pemphigus erythematosus in a Korea Jindo dog. / Bhang, Dong Ha; Choi, Ul Soo; Jung, Yun Chan; Kim, Min Kyu; Choi, Eun Wha; Seo, Kyoung Won; Kang, Min Soo; Hwang, Cheol Yong; Kim, Dae Yong; Youn, Hwa Young; Lee, Chang Woo.
In: Journal of Veterinary Medical Science, Vol. 70, No. 4, 01.04.2008, p. 415-417.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Topical 0.03% tacrolimus for treatment of pemphigus erythematosus in a Korea Jindo dog
AU - Bhang, Dong Ha
AU - Choi, Ul Soo
AU - Jung, Yun Chan
AU - Kim, Min Kyu
AU - Choi, Eun Wha
AU - Seo, Kyoung Won
AU - Kang, Min Soo
AU - Hwang, Cheol Yong
AU - Kim, Dae Yong
AU - Youn, Hwa Young
AU - Lee, Chang Woo
PY - 2008/4/1
Y1 - 2008/4/1
N2 - Topical 0.03% tacrolimus was used for treatment of a Korea Jindo dog diagnosed with pemphigus erythematosus. The dog was slowly improved following application of tacrolimus but did not achieve complete remission until end of this study. No adverse effects on clinical or laboratory parameters were noted during the topical tacrolimus therapy period.
AB - Topical 0.03% tacrolimus was used for treatment of a Korea Jindo dog diagnosed with pemphigus erythematosus. The dog was slowly improved following application of tacrolimus but did not achieve complete remission until end of this study. No adverse effects on clinical or laboratory parameters were noted during the topical tacrolimus therapy period.
KW - Canine
KW - Pemphigus erythematosus
KW - Topical 0.03% tacrolimus
UR - http://www.scopus.com/inward/record.url?scp=43249095054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43249095054&partnerID=8YFLogxK
U2 - 10.1292/jvms.70.415
DO - 10.1292/jvms.70.415
M3 - Article
C2 - 18460840
AN - SCOPUS:43249095054
VL - 70
SP - 415
EP - 417
JO - Journal of Veterinary Medical Science
JF - Journal of Veterinary Medical Science
SN - 0916-7250
IS - 4
ER -